Estrogens, Esterified
drugOn this page
Also known as AmnestrogenEsterified estrogensEstratabEstrogens esterifiedEstrogensesterifiedesterified component of menriumEvexFemogenMenest
Summary
Estrogens, Esterified (CHEMBL1201468) is an approved unknown; indicated across 5 conditions including breast neoplasm and primary ovarian failure.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- Indications: 5 conditions
- Clinical trials: 3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201468 |
| Name | Estrogens, Esterified |
| Type | Unknown |
| Max phase | 4 |
Also known as: Amnestrogen, Esterified estrogens, Estratab, Estrogens esterified, Estrogens, esterified, esterified component of menrium, Evex, Femogen, Menest, ESTROGENS, ESTERIFIED
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| breast neoplasm | 4 | MONDO:0021100 | MONDO:0007254 |
| primary ovarian failure | 4 | MONDO:0005387 | EFO:0004266 |
| hypogonadism | 4 | MONDO:0002146 | MONDO:0002146 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00131924 | PHASE2 | TERMINATED | High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy |
| NCT00141544 | PHASE2 | TERMINATED | The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women |
| NCT00141557 | PHASE2 | TERMINATED | The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: breast neoplasm, primary ovarian failure, hypogonadism